Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma-Reference-Cited by-同舟云学术

Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma

Published:2024-06-11 Issue:16 Volume:30 Page:3358-3360
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Ohmura Shunya¹²³^ORCID,Grünewald Thomas G. P.¹²³⁴^ORCID

Affiliation:

1. Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany. 1

2. Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. 2

3. National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany. 3

4. Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany. 4

Abstract

Summary EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacologic ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repair, and translation machinery, which could maximize the therapeutic window of the combinatory therapy. See related article by Jess et al., p. 3533

Funder

Dr. Rolf M. Schwiete foundation

Barbara and Wilfried Mohr foundation

European Research Council

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-24-1047/3461750/ccr-24-1047.pdf

Reference13 articles.

1. Cell Context is the third axis of synergy for the combination of ATR inhibition and cisplatin in Ewing sarcoma;Jess;Clin Cancer Res,2024

2. Ewing sarcoma;Grunewald;Nat Rev Dis Primers,2018

3. Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies;Knott;Cancer Metastasis Rev,2019

4. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent;Uren;Future Oncol,2005

5. EWS/FLI1 target genes and therapeutic opportunities in Ewing sarcoma;Cidre-Aranaz;Front Oncol,2015